Skip to Content

Glecaprevir / pibrentasvir Pregnancy and Breastfeeding Warnings

Glecaprevir / pibrentasvir is also known as: Mavyret

Glecaprevir / pibrentasvir Pregnancy Warnings

Animal studies with glecaprevir have failed to reveal evidence of embryofetal toxicity in rats (exposures up to 53 times the exposure in humans at the recommended human dose [RHD]); in rabbits, maternal toxicity (anorexia, lower body weight, lower body weight gain) with some embryofetal toxicity (increased postimplantation loss, increased number of resorptions, decreased fetal body weight) prevented evaluation of glecaprevir at clinical exposures (highest exposure reached in rabbits was 0.07 times the exposure in humans at RHD). Animal studies with pibrentasvir have failed to reveal evidence of embryofetal toxicity in mice and rabbits (exposures up to 51 and 1.5 times the exposure in humans at RHD, respectively). There are no controlled data in human pregnancy. US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

According to some authorities: As a precaution, use is not recommended. US FDA pregnancy category: Not assigned. Risk summary: No adequate data available on use of this drug in pregnant women to inform a drug-related risk.

See references

Glecaprevir / pibrentasvir Breastfeeding Warnings

According to some authorities: A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother and the benefit of breastfeeding for the child. Excreted into human milk: Unknown Excreted into animal milk: Yes (both components) Comments: -Developmental and health benefits of breastfeeding should be considered as well as the mother's clinical need for this drug. -The effects in the nursing infant are unknown; potential side effects in the breastfed child due to this drug or the mother's underlying condition should be considered.

See references

References for pregnancy information

  1. "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

References for breastfeeding information

  1. "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide